



HEALTHCARE

## **Delivery Mechanisms for Large Molecule Drugs**

Successes and failures of leading technologies and key drivers for market success

Isabel Fraser-Moodie

 [Table of Contents](#)

## **Isabel Fraser-Moodie**

Isabel Fraser-Moodie is an analyst within the healthcare practice of Business Insights. She previously worked in the competitive intelligence for multinational pharmaceutical corporations. Her areas of interest are drug discovery, R&D innovation and science policy, specifically related to commercialization of new medical innovations. Isabel graduated with a Master's degree in Natural Sciences from Cambridge University, where she specialized in legislation targeting emerging genetic therapeutics and diagnostics.

Copyright © 2008 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved.  
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Delivery Mechanisms for Large Molecule Drugs

<b>Executive summary</b>	<b>10</b>
Introduction	10
Drivers for new platform developments	11
Resistors of change	12
Key emerging technologies	13
Systemic targeting technologies	14
Ease of use systems	15
Conclusions	16
<b>Chapter 1           Introduction</b>	<b>18</b>
Summary	18
Introduction	19
The emergence of large molecule therapeutics	21
Definitions	23
Technology platform definitions	23
Product coverage	25
Market coverage	25
Leading technologies coverage	27
The measures for market success	28
<b>Chapter 2           Drivers of new platform                           developments</b>	<b>30</b>
Summary	30
Introduction	31
The growth of the large molecule market	32
Therapy area growth drivers	33
Clinical development spend	35

Cost-effective manufacturing	36
Existing failure rates	36
<b>Unmet clinical needs</b>	<b>38</b>
Boosting patient compliance	39
Overcoming stability, bioavailability and toxic effects	40
Improving efficacy	40
<b>Chapter 3</b>	<b>Risk, costs and technology maturity</b>
	<b>42</b>
<b>Summary</b>	<b>42</b>
<b>Introduction</b>	<b>43</b>
<b>Risk of failure with new technologies</b>	<b>43</b>
Unknown drug candidate pharmacokinetics	45
Solubility and instability with oral candidates	45
Bioavailability	46
Toxicity and unknown long-term effects	47
The shifting regulatory framework	47
Case study: Insulin delivery and investor confidence	48
<b>The impact of cost and revenue on the decision to innovate</b>	<b>51</b>
<b>Immaturity concerns</b>	<b>52</b>
<b>Maturity of the delivery technologies</b>	<b>52</b>
<b>Chapter 4</b>	<b>Key emerging technologies</b>
	<b>58</b>
<b>Summary</b>	<b>58</b>
<b>The forecast market impact</b>	<b>59</b>
<b>Nanotechnology to enhance solubility profiles</b>	<b>60</b>
The evolving nanotechnology industry	61
The development pipeline	63
Leading clinical applications	64
Parenteral delivery systems	66
Dermal platform systems	67
Nanostructured materials; oral and depot system use	68
Novel oral drug delivery systems	68
Investigative nanoshells, nanofilms and active control	69
<b>Advances in microelectronics</b>	<b>71</b>
Existing electronic applications	71
The development pipeline for microelectronics	73
Microchip technologies	73
Inkjet technology for drug delivery	74

## **Chapter 5                      Systemic targeting techniques                      78**

<b>Summary</b>	<b>78</b>
<b>Introduction</b>	<b>79</b>
<b>Systemic passive targeting techniques</b>	<b>81</b>
Stealth technologies: Immune system evasion	81
PEGylation technologies	83
PEGylation in clinical pipelines	84
Preclinical PEGylation investigation	86
The limitations of PEG	86
Next generation PEGylation	87
<b>Systemic active targeting techniques</b>	<b>88</b>
Antibody techniques	89
Antibody fragments	90
Binding specificity	91
Novel combination technologies to improve targeting	92
Cost-effective manufacture	93
The development pipeline	94
The emergence of IgG4 antibody therapies	94
Small modular Immunopharmaceuticals as antibody alternatives	95
Pipeline novel conjugate technologies	96
Antibody fragments in targeted carrier systems	96
Investigational protein carrier Prodrug complexes	97
Clotting factor conjugate targeting	97
Molecular trojan horse techniques	98

## **Chapter 6                      Ease of use systems                      102**

<b>Summary</b>	<b>102</b>
<b>Introduction</b>	<b>103</b>
<b>Pulmonary delivery technologies</b>	<b>104</b>
Particle engineering technologies for pulmonary delivery	105
Vaporization techniques and delivery control	106
Applications of electronics	106
<b>Needle-free transdermal delivery</b>	<b>107</b>
Leading technology platforms	109
Needle-free pressure-based systems	110
Microinjection platforms for intra-epidermal delivery	110
EMA filing for first microinjection system	111
technology platform	112
Electrotransport systems	113
Electroporation in transdermal delivery	113
TransPharma Medical ltd's RF-Microchannel technology	114
Novel approaches to active intra-epidermal delivery	115
Laser drug delivery systems	115

Thermal energy platform	116
-------------------------	-----

## **Chapter 7                      Conclusions                      118**

<b>Summary</b>	<b>118</b>
<b>Introduction</b>	<b>119</b>
Pharma vs biotech large molecule R&D investment	119
<b>Leading technologies</b>	<b>121</b>
Growth in particle engineering technologies	121
The impact of new routes of administration	122
Large molecule drug delivery market growth and maturity	123
<b>Current and future market impact</b>	<b>127</b>
Therapy area impact	127
Timeline of impact	130
<b>Summary of technology success and impact</b>	<b>133</b>

## **Appendix                      136**

<b>Index</b>	<b>136</b>
<b>Methodology</b>	<b>137</b>
<b>Methodology</b>	<b>137</b>
MedTRACK platform identification	137
<b>Glossary</b>	<b>138</b>

# List of Figures

Figure 1.1:	The role of drug delivery in the product R&D pipeline	20
Figure 1.2:	Biopharmaceutical company dependence on large molecule drugs*	22
Figure 1.3:	Defining the pathway from proprietary technology to clinical use	24
Figure 2.4:	The global pipeline for chemical and biologic drugs, October 2008	33
Figure 2.5:	Number of pipeline biologic drug candidates and products, by therapy area, October 2008	34
Figure 2.6:	Pharma R&D spend 2004-2009e	35
Figure 2.7:	Biotech R&D spend (\$bn), 2004-2009e	36
Figure 2.8:	Pharmacokinetic effects; resistors of market growth and opportunity for new technologies	38
Figure 3.9:	Key innovative technologies, clinical drug failures and discontinued products, November 2008	44
Figure 3.10:	Development pipeline for insulin devices, human insulins and analogues, October 2008	49
Figure 3.11:	Discontinued insulin devices, human insulins and analogues, platforms for delivery, per year 2001-2008	51
Figure 3.12:	Key particle engineering technologies; industry size and maturity	54
Figure 3.13:	Key route of administration technologies; industry size and maturity	55
Figure 4.14:	Investment deals and clinical applications in nanotechnology drug delivery platforms, 2002-Q2 2008	62
Figure 4.15:	Product pipeline; large molecule nanotechnology innovations	64
Figure 4.16:	Maturity of electronic active delivery platforms in transmembrane and pulmonary delivery systems	72
Figure 5.17:	The market advantage of targeted drugs	80
Figure 5.18:	Passive targeting strategies for large molecule delivery	81
Figure 5.19:	The benefits of PEGylation to improve pharmacological profiles	83
Figure 5.20:	Active targeting strategies for large molecule delivery	88
Figure 5.21:	The global MAb product pipeline by phase, Q4 2008	89
Figure 5.22:	Antibody fragmentation platforms – Competitive advantage	90
Figure 5.23:	Antibody fragments: separating targeting domains	92
Figure 6.24:	Transdermal and transmembrane active platform technologies, November 2008	108
Figure 6.25:	Investment in and maturity of active transdermal delivery	109
Figure 7.26:	Big biotech v big pharma large molecule patent applications, 2003-2007, global	120
Figure 7.27:	Particle engineering technologies in drug R&D pipelines, by phase, October 2008	122
Figure 7.28:	Industry growth and investment, leading innovative drug delivery platforms	124
Figure 7.29:	Growth in technology deals; 1998-2007	126
Figure 7.30:	Impact of new technology platforms developments on therapy area pipelines	127
Figure 7.31:	Therapy area focus of innovative technology product candidates, October 2008	128
Figure 7.32:	New medical device technologies, anticipated market impact	129
Figure 7.33:	Emerging particle engineering technologies, anticipated market impact	130
Figure 7.34:	The impact of new delivery technologies; timeline for success	131
Figure 7.35:	Measures of technology success	133

# List of Tables

Table 1.1:	Nektar's leading innovative technology pipeline	25
Table 1.2:	Needle free delivery; Key routes of administration	26
Table 1.3:	Technology market coverage	27
Table 2.4:	The global pipeline for chemical and biologic drugs, October 2008	37
Table 3.5:	Key innovative technologies, clinical drug failures and discontinued products, November 2008	45
Table 3.6:	Key route of administration technologies; industry size and maturity	56
Table 4.7:	Nanotechnology drug delivery platforms, large molecule vs small molecule applications, November 2008	63
Table 4.8:	Nanoparticles as drug delivery carriers	64
Table 4.9:	Leading clinical parenteral drug delivery	66
Table 5.10:	Clinical PEGylation stealth targeting technologies	84
Table 5.11:	Antibody fragment products, clinical applications	93
Table 5.12:	Armagen's proprietary CNS product pipeline: Trojan horse conjugate delivery	99
Table 6.13:	Small molecule success of membrane transport technologies, November 2008	106
Table 6.14:	Clinical use electronic pulmonary delivery technologies	107
Table 6.15:	Transdermal and transmembrane active platform technologies, November 2008	108
Table 6.16:	Novel electroporation platforms; transdermal alternatives	113
Table 7.17:	Innovative technology products in R&D pipelines, October 2008	123
Table 7.18:	Industry maturity and investment, leading innovative drug delivery platforms	125
Table 7.19:	Growth in technology deals, 1998-2007	126
Table 7.20:	Therapy area focus of innovative technology product candidates, October 2008	129